387 PROSPECTIVE EVALUATION OF CELL CYCLE BIOMARKERS FOR PREDICTION OF CANCER-SPECIFIC MORTALITY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Aditya Bagrodia ◽  
Ramy Youssef ◽  
Oussama Darwish ◽  
Chase Cannon ◽  
Michael Belsante ◽  
...  
2018 ◽  
Vol 13 (9) ◽  
Author(s):  
Hanan Goldberg ◽  
Douglas C. Cheung ◽  
Thenappan Chandrasekar ◽  
Zachary Klaassen ◽  
Christopher J.D. Wallis ◽  
...  

Introduction: Upper tract urothelial carcinoma (UTUC) accounts for <5% of all urothelial cancers. We aimed to ascertain the clinical differences between UTUC tumours presenting de novo (DnUTUC) and those presenting secondary (SUTUC) following a bladder cancer diagnosis. Methods: Our institutional database was queried for all UTUC patients who were surgically treated with radical nephroureterectomy or ureterectomy between 2003 and 2017. Bladder recurrence and cancer-specific mortality were compared. To reduce the possible bias due to confounding variables obtained from a simple comparison of outcomes, DnUTUC patients were matched (for age, gender, tumour location, type of surgery, grade, TNM staging, presence of carcinoma in situ, and lymphovascular invasion) with propensity score to SUTUC patients. Bladder recurrence and cancer-specific mortality were assessed with Cox proportional hazards model. Results: A total of 117 UTUC patients were identified: 80 with DnUTUC (68.4%) and 37 with SUTUC (31.6%). A greater proportion of males with SUTUC was demonstrated (89.2% vs. 68.8; p=0.02). In both groups, 67.5% of patients had high-grade disease, but SUTUC demonstrated a higher carcinoma in situ rate (43.2% vs. 25%; p=0.047). Univariate analysis demonstrated that the five-year bladder recurrence rate was trending to be higher in SUTUC (65.3% vs. 20.5%; p=0.099). In the Cox model, however, it was associated with increased bladder recurrence (hazard ratio [HR] 3.69; 95% confidence interval [CI] 1.68–8.09; p=0.001). Although univariate analysis demonstrated that SUTUC patients were more likely to die of their disease (30.6% vs. 9%; p=0.009), the multivariable Cox model did not demonstrate this association. The limitations of this study include its retrospective, single-centre design and relatively small cohort of patients. Conclusions: In this hypothesis-generating study, some evidence suggests that further research is needed to delineate differences between SUTUC and DnUTUC.


2016 ◽  
Vol 12 (1) ◽  
pp. 183-188 ◽  
Author(s):  
QIUBO YU ◽  
YANAN LI ◽  
GANG LI ◽  
TINGHONG LI ◽  
HAN ZENG ◽  
...  

2020 ◽  
Vol 3 (3) ◽  
pp. 153-160
Author(s):  
Panagiotis J Vlachostergios

Abstract Upper tract urothelial carcinoma (UTUC) is rare but can occur sporadically outside the context of Lynch syndrome. In these cases, knowing whether non-mismatch repair (MMR), DNA damage response and repair (DDR), and cell cycle gene alterations may predict responses to chemotherapy or immunotherapy and survival is of clinical importance. This study examined the germline and somatic mutational landscape of two UTUC patients with differential responses to programmed death 1 (PD-1)/PD-ligand 1 (PD-L1) immune checkpoint inhibitors and queried three independent UTUC cohort studies for co-occurrence of key cell cycle and DDR genes, as well as for their associations with overall survival (OS). TP53 and RB1 emerged as potential determinants of shorter OS in UTUC cohort patients, regardless of concurrent DDR alterations, and if prospectively assessed in larger studies they might also explain resistance to PD-1/PD-L1 blockade despite PD-L1 expression.


Sign in / Sign up

Export Citation Format

Share Document